CN104302625B - 吡唑衍生物及其作为lpar5拮抗剂的用途 - Google Patents
吡唑衍生物及其作为lpar5拮抗剂的用途 Download PDFInfo
- Publication number
- CN104302625B CN104302625B CN201380025967.9A CN201380025967A CN104302625B CN 104302625 B CN104302625 B CN 104302625B CN 201380025967 A CN201380025967 A CN 201380025967A CN 104302625 B CN104302625 B CN 104302625B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- methyl
- phenyl
- benzoic acid
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C(COCC(*)=O)=**1c(cc2)c(*)cc2N)=C1c(cc1)ccc1N Chemical compound CC(C(COCC(*)=O)=**1c(cc2)c(*)cc2N)=C1c(cc1)ccc1N 0.000 description 1
- ZFKVLZREWLDRFB-SYHGKFOUSA-N CC(C(Nc(cc1)ccc1C(O)=O)=O)OC/C(/NC)=C(\CCC=C1)/C1=N Chemical compound CC(C(Nc(cc1)ccc1C(O)=O)=O)OC/C(/NC)=C(\CCC=C1)/C1=N ZFKVLZREWLDRFB-SYHGKFOUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305552 | 2012-05-18 | ||
| EP12305552.7 | 2012-05-18 | ||
| PCT/EP2013/060171 WO2013171317A1 (en) | 2012-05-18 | 2013-05-16 | Pyrazole derivatives and their use as lpar5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104302625A CN104302625A (zh) | 2015-01-21 |
| CN104302625B true CN104302625B (zh) | 2017-04-19 |
Family
ID=48446368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380025967.9A Expired - Fee Related CN104302625B (zh) | 2012-05-18 | 2013-05-16 | 吡唑衍生物及其作为lpar5拮抗剂的用途 |
Country Status (22)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015521183A (ja) | 2012-05-18 | 2015-07-27 | サノフイ | ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 |
| AU2016277126A1 (en) * | 2015-06-12 | 2017-12-14 | Vettore, LLC | MCT4 inhibitors for treating disease |
| BR112019011825A2 (pt) | 2016-12-12 | 2019-10-22 | Vettore, LLC | composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente |
| KR20220077140A (ko) | 2019-10-02 | 2022-06-08 | 도메인 테라퓨틱스 | 프로스타글란딘 e2(pge2) ep4 수용체 길항제 |
| WO2024092205A1 (en) * | 2022-10-27 | 2024-05-02 | The Trustees Of Indiana University | Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease |
| CN119930520B (zh) * | 2023-11-03 | 2026-03-06 | 中国药科大学 | N-芳基吡唑类化合物及其药物组合物和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945855A (zh) * | 2008-03-07 | 2011-01-12 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1、cx3cr1表达的疾病中的用途 |
| WO2011015501A1 (en) * | 2009-08-03 | 2011-02-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Process for the preparation of 1-benzyl-3-hydr0xymethyl-1h-indaz0le and its derivatives and required magnesium intermediates |
| WO2012028243A1 (en) * | 2010-09-02 | 2012-03-08 | Merck Patent Gmbh | Pyrazolopyridinone derivatives as lpa receptor antagonists |
| CN102439003A (zh) * | 2009-03-19 | 2012-05-02 | 赛诺菲 | 抑制hsp90的吲唑衍生物、含有所述衍生物的组合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1230441B (it) | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| US7279478B2 (en) | 2002-09-04 | 2007-10-09 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| MX2010009625A (es) | 2008-03-07 | 2010-09-28 | Acraf | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. |
| JP2015521183A (ja) | 2012-05-18 | 2015-07-27 | サノフイ | ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 |
-
2013
- 2013-05-16 DK DK13723151.0T patent/DK2882715T3/en active
- 2013-05-16 HU HUE13723151A patent/HUE032890T2/hu unknown
- 2013-05-16 HR HRP20170098TT patent/HRP20170098T1/hr unknown
- 2013-05-16 AU AU2013261718A patent/AU2013261718B2/en not_active Ceased
- 2013-05-16 MX MX2014014011A patent/MX347615B/es active IP Right Grant
- 2013-05-16 PT PT137231510T patent/PT2882715T/pt unknown
- 2013-05-16 ES ES13723151.0T patent/ES2612205T3/es active Active
- 2013-05-16 BR BR112014028406A patent/BR112014028406A2/pt not_active Application Discontinuation
- 2013-05-16 KR KR20147033843A patent/KR20150010973A/ko not_active Ceased
- 2013-05-16 EP EP13723151.0A patent/EP2882715B1/en not_active Not-in-force
- 2013-05-16 SI SI201330499A patent/SI2882715T1/sl unknown
- 2013-05-16 SG SG11201407210SA patent/SG11201407210SA/en unknown
- 2013-05-16 PL PL13723151T patent/PL2882715T3/pl unknown
- 2013-05-16 LT LTEP13723151.0T patent/LT2882715T/lt unknown
- 2013-05-16 US US14/401,050 patent/US9346762B2/en not_active Expired - Fee Related
- 2013-05-16 CA CA2871542A patent/CA2871542A1/en not_active Abandoned
- 2013-05-16 WO PCT/EP2013/060171 patent/WO2013171317A1/en not_active Ceased
- 2013-05-16 RU RU2014151360A patent/RU2645344C2/ru not_active IP Right Cessation
- 2013-05-16 JP JP2015512072A patent/JP6257596B2/ja not_active Expired - Fee Related
- 2013-05-16 CN CN201380025967.9A patent/CN104302625B/zh not_active Expired - Fee Related
-
2014
- 2014-10-20 IL IL235221A patent/IL235221A/en active IP Right Grant
-
2017
- 2017-02-08 CY CY20171100175T patent/CY1118618T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945855A (zh) * | 2008-03-07 | 2011-01-12 | 方济各安吉利克化学联合股份有限公司 | 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1、cx3cr1表达的疾病中的用途 |
| CN102439003A (zh) * | 2009-03-19 | 2012-05-02 | 赛诺菲 | 抑制hsp90的吲唑衍生物、含有所述衍生物的组合物及其用途 |
| WO2011015501A1 (en) * | 2009-08-03 | 2011-02-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Process for the preparation of 1-benzyl-3-hydr0xymethyl-1h-indaz0le and its derivatives and required magnesium intermediates |
| WO2012028243A1 (en) * | 2010-09-02 | 2012-03-08 | Merck Patent Gmbh | Pyrazolopyridinone derivatives as lpa receptor antagonists |
Non-Patent Citations (3)
| Title |
|---|
| Design, synthesis and biological evaluation of CB1 cannabinoid 1,5-diarylpyrazole;GuoGang Tu,等;《Journal of Enzyme Inhibition and Medicinal Chemistry》;20111231;第26卷(第2期);222-230 * |
| Nonpeptide Factor Xa Inhibitors: DPC423, A Highly Potent and Orally Bioavailable Pyrazole Antithrombotic Agent;Pancras C. Wong,等;《Cardiovascular Drug Reviews》;20021231;第20卷(第2期);137-152 * |
| Synthesis, structure and inhibitory effects on cyclooxygenase,lipoxygenase, thromboxane synthetase and platelet aggregation of 3-amino-4,5-dihydro-1H-pyrazole derivatives;Jordi FRIGOLA,等;《Eur. J. Med. Chem.》;19891231;第24卷;435-445 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2882715A1 (en) | 2015-06-17 |
| MX2014014011A (es) | 2015-02-12 |
| RU2014151360A (ru) | 2016-07-10 |
| AU2013261718A1 (en) | 2014-12-18 |
| BR112014028406A2 (pt) | 2017-06-27 |
| CN104302625A (zh) | 2015-01-21 |
| CY1118618T1 (el) | 2017-07-12 |
| US9346762B2 (en) | 2016-05-24 |
| AU2013261718B2 (en) | 2017-10-19 |
| WO2013171317A1 (en) | 2013-11-21 |
| HUE032890T2 (hu) | 2017-11-28 |
| PL2882715T3 (pl) | 2017-04-28 |
| LT2882715T (lt) | 2017-02-10 |
| PT2882715T (pt) | 2016-12-30 |
| RU2645344C2 (ru) | 2018-02-21 |
| JP2015517514A (ja) | 2015-06-22 |
| IL235221A (en) | 2016-06-30 |
| CA2871542A1 (en) | 2013-11-21 |
| US20150141477A1 (en) | 2015-05-21 |
| HRP20170098T1 (hr) | 2017-03-24 |
| JP6257596B2 (ja) | 2018-01-10 |
| MX347615B (es) | 2017-05-04 |
| SI2882715T1 (sl) | 2017-03-31 |
| DK2882715T3 (en) | 2017-02-13 |
| KR20150010973A (ko) | 2015-01-29 |
| EP2882715B1 (en) | 2016-11-09 |
| ES2612205T3 (es) | 2017-05-12 |
| SG11201407210SA (en) | 2014-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101589332B1 (ko) | 2h-크로멘 화합물 및 그의 유도체 | |
| JP5309033B2 (ja) | ヘテロアリールシクロプロパンカルボキサミド及び薬剤としてのその使用 | |
| CN104302625A (zh) | 吡唑衍生物及其作为lpar5拮抗剂的用途 | |
| CZ297544B6 (cs) | Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy | |
| JPWO2001074791A1 (ja) | ジアゼパン誘導体又はその塩 | |
| CN116262724A (zh) | 新型氧代吡啶类化合物及其制备方法和用途 | |
| JP2004512267A (ja) | 第Xa因子のラクタム系阻害剤および方法 | |
| US9346757B2 (en) | Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation | |
| CN104302633B (zh) | 苯并[1,3]二氧杂环己烯衍生物和它们作为lpar5 拮抗剂的应用 | |
| US5602149A (en) | 1-OXO-2-(phenylsulphonylamino)pentypiperidine derivatives, their preparation and their therapeutic application | |
| JP2004520399A (ja) | トロンビン阻害剤 | |
| CN101550115B (zh) | 一种取代哌嗪基烷氧基联苄类化合物、制备方法及医药用途 | |
| JP4660197B2 (ja) | 2−(5−クロロチエン−2−イル)−n−{(3s)−1−[(1s)−1−メチル−2−モルホリン−4−イル−2−オキソエチル]−2−オキソピロリジン−3−イル}エテンスルホンアミドの結晶性誘導体 | |
| CN101712659B (zh) | 一种具有抗血小板聚集活性的化合物及其制备方法 | |
| JP2019537586A (ja) | (1R,2R)−2−[4−(3−メチル−1H−ピラゾール−5−イル)ベンゾイル]−N−(4−オキソ−4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン−3−イル)シクロヘキサンカルボキサミド | |
| JPWO1998027061A1 (ja) | N−[(置換5員ヘテロアリール)カルボニル]グアニジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170419 Termination date: 20200516 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |